Promacta Kit
(Eltrombopag Olamine)ApprovedSmall molecule
NovartisPromacta Kit is one of 5 small molecule programs targeting Stem Cell. It is currently in Approved.
2
Indications
11
Total Trials
1
Active Trials
4
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in Thrombocytopenic Purpura
#DrugCompanyPhaseTrials
1Promacta Kit
NovartisApproved
CABLIVI
GGenzyme, a Sanofi Company
Preclinical
Inactivated Trivalent Influenza Vaccine
AAdvagene Biopharma Co. Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia1 trial
Anemia1 trial
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Completed·—·Phase 2·NCT01772420·52 enrolled
Myelodysplastic Syndrome1 trial
6 more indications
Thrombocytopenic Purpura1 trial
Myeloid Leukemia1 trial
Safety and Efficacy1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Oct 20, 2011
PROMACTA
NDA NDA022291
Sep 27, 2018
PROMACTA KIT
NDA NDA207027
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eltrombopag Olamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Patent Landscape[5]
Patent Cliff
Aug 1, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7547719Jul 13, 2025
7547719*PEDJan 13, 2026
8052994Aug 1, 2027
8828430Aug 1, 2027
8071129Aug 1, 2027
7 more patents
8062665Aug 1, 2027
8052993Aug 1, 2027
8071129*PEDFeb 1, 2028
8828430*PEDFeb 1, 2028
8052993*PEDFeb 1, 2028
8052994*PEDFeb 1, 2028
8062665*PEDFeb 1, 2028